BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 17824682)

  • 1. Autoantibody signature in human ductal pancreatic adenocarcinoma.
    Tomaino B; Cappello P; Capello M; Fredolini C; Ponzetto A; Novarino A; Ciuffreda L; Bertetto O; De Angelis C; Gaia E; Salacone P; Milella M; Nisticò P; Alessio M; Chiarle R; Giuffrida MG; Giovarelli M; Novelli F
    J Proteome Res; 2007 Oct; 6(10):4025-31. PubMed ID: 17824682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma.
    Hwang TL; Liang Y; Chien KY; Yu JS
    Proteomics; 2006 Apr; 6(7):2259-72. PubMed ID: 16493704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer.
    Hong SH; Misek DE; Wang H; Puravs E; Giordano TJ; Greenson JK; Brenner DE; Simeone DM; Logsdon CD; Hanash SM
    Cancer Res; 2004 Aug; 64(15):5504-10. PubMed ID: 15289361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas.
    Qi T; Han J; Cui Y; Zong M; Liu X; Zhu B
    J Clin Pathol; 2008 Jan; 61(1):49-58. PubMed ID: 17412869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen.
    Cappello P; Tomaino B; Chiarle R; Ceruti P; Novarino A; Castagnoli C; Migliorini P; Perconti G; Giallongo A; Milella M; Monsurrò V; Barbi S; Scarpa A; Nisticò P; Giovarelli M; Novelli F
    Int J Cancer; 2009 Aug; 125(3):639-48. PubMed ID: 19425054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer.
    Tomaino B; Cappello P; Capello M; Fredolini C; Sperduti I; Migliorini P; Salacone P; Novarino A; Giacobino A; Ciuffreda L; Alessio M; Nisticò P; Scarpa A; Pederzoli P; Zhou W; Petricoin Iii EF; Liotta LA; Giovarelli M; Milella M; Novelli F
    J Proteome Res; 2011 Jan; 10(1):105-12. PubMed ID: 20455595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4.
    Takehara A; Eguchi H; Ohigashi H; Ishikawa O; Kasugai T; Hosokawa M; Katagiri T; Nakamura Y; Nakagawa H
    Cancer Sci; 2006 Nov; 97(11):1191-7. PubMed ID: 16918991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma.
    Chung JC; Oh MJ; Choi SH; Bae CD
    ANZ J Surg; 2008 Apr; 78(4):245-51. PubMed ID: 18366394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Actinin-4 expression in primary and metastasized pancreatic ductal adenocarcinoma.
    Welsch T; Keleg S; Bergmann F; Bauer S; Hinz U; Schmidt J
    Pancreas; 2009 Nov; 38(8):968-76. PubMed ID: 19672209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunohistochemical study of mucins in chronic pancreatitis and ductal adenocarcinoma of the pancreas].
    Paklina OV; Setdikova GR
    Arkh Patol; 2008; 70(4):13-7. PubMed ID: 18807519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and potential function of the CXC chemokine CXCL16 in pancreatic ductal adenocarcinoma.
    Wente MN; Gaida MM; Mayer C; Michalski CW; Haag N; Giese T; Felix K; Bergmann F; Giese NA; Friess H
    Int J Oncol; 2008 Aug; 33(2):297-308. PubMed ID: 18636150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models.
    Capello M; Cappello P; Linty FC; Chiarle R; Sperduti I; Novarino A; Salacone P; Mandili G; Naccarati A; Sacerdote C; Beghelli S; Bersani S; Barbi S; Bassi C; Scarpa A; Nisticò P; Giovarelli M; Vineis P; Milella M; Novelli F
    J Hematol Oncol; 2013 Sep; 6():67. PubMed ID: 24010981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma.
    Szafranska AE; Davison TS; John J; Cannon T; Sipos B; Maghnouj A; Labourier E; Hahn SA
    Oncogene; 2007 Jun; 26(30):4442-52. PubMed ID: 17237814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of MSX2 mRNA in brush cytology specimens distinguished pancreatic carcinoma from chronic pancreatitis.
    Satoh K; Hamada S; Kanno A; Ishida K; Ito H; Hirota M; Masamune A; Egawa S; Unno M; Shimosegawa T
    Cancer Sci; 2011 Jan; 102(1):157-61. PubMed ID: 20961362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BGLAP is expressed in pancreatic cancer cells and increases their growth and invasion.
    Kayed H; Bekasi S; Keleg S; Michalski CW; Giese T; Friess H; Kleeff J
    Mol Cancer; 2007 Dec; 6():83. PubMed ID: 18163903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma.
    Turtoi A; Musmeci D; Wang Y; Dumont B; Somja J; Bevilacqua G; De Pauw E; Delvenne P; Castronovo V
    J Proteome Res; 2011 Sep; 10(9):4302-13. PubMed ID: 21755970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients.
    Tanaka M; Komatsu N; Terakawa N; Yanagimoto Y; Oka M; Sasada T; Mine T; Gouhara S; Shichijo S; Okuda S; Itoh K
    Oncol Rep; 2007 Jul; 18(1):161-6. PubMed ID: 17549363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression analysis of PMP22/Gas3 in premalignant and malignant pancreatic lesions.
    Li J; Kleeff J; Esposito I; Kayed H; Felix K; Giese T; Büchler MW; Friess H
    J Histochem Cytochem; 2005 Jul; 53(7):885-93. PubMed ID: 15995147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
    Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
    Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients.
    Sanlioglu AD; Dirice E; Elpek O; Korcum AF; Ozdogan M; Suleymanlar I; Balci MK; Griffith TS; Sanlioglu S
    Pancreas; 2009 Mar; 38(2):154-60. PubMed ID: 18981952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.